16 Abr Selective modulation of GPR55 receptor, a new and promising approach for the treatment of diseases and pain.
[three_fourth_last][box] CSIC and University of Toronto have found a new family of chromenopyrazole derivatives which act as modulators of the G-protein-coupled receptor 55 (GPR55). Therefore, these compounds are useful for the treatment of pathologies and disorders where GPR55 receptor is relevant, such as diabetes, cancer, inflammatory and neuropathic pain, bone diseases, Parkinson disease and multiple sclerosis. They might be also useful as pharmacological tools. Pharmaceutical companies interested in a patent licence are sought.[/box]